The survival of 90% of a tumor-bearing population treated with the complex Rh2
(CF3CONH)4
was
examined and the pharmacological parameter Surv90
determined. Histopathological alterations raised for this
drug in several tissues were studied in Balb-c mice. A
Surv90
dose of 3.8x 10-5
mol/kg was found